Gangadhar Sunkara, Ph.D.
Affiliations: | 2002 | University of Nebraska Medical Center, Omaha, NE, United States |
Area:
Pharmacy, Pharmaceutical Chemistry, OphthalmologyGoogle:
"Gangadhar Sunkara"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Uday B. Kompella | grad student | 2002 | University of Nebraska Medical Center | |
| (Transport, pharmacokinetics and ocular delivery of N-4-[(benzoylamino)phenylsulfonyl]glycine, an aldose reductase inhibitor.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kovacs SJ, Ting L, Praestgaard J, et al. (2020) An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline. Antimicrobial Agents and Chemotherapy |
| Schuehly U, Ayalasomayajula S, Buchbjerg J, et al. (2018) Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. European Journal of Clinical Pharmacology |
| Ayalasomayajula S, Schuehly U, Pal P, et al. (2018) Effect of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan on pharmacokinetics and pharmacodynamics of a single-dose of furosemide. British Journal of Clinical Pharmacology |
| Jain JP, Leong FJ, Chen L, et al. (2017) Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach: A randomized, open-label pharmacokinetic study in healthy volunteers. Antimicrobial Agents and Chemotherapy |
| Hsiao HL, Langenickel TH, Petruck J, et al. (2017) Evaluation of pharmacokinetic and pharmacodynamic drug-drug interaction of sacubitril/valsartan (LCZ696) and sildenafil in patients with mild-to-moderate hypertension. Clinical Pharmacology and Therapeutics |
| Ayalasomayajula S, Langenickel T, Pal P, et al. (2017) Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics |
| Ayalasomayajula S, Langenickel T, Pal P, et al. (2017) Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics |
| Sun H, Ting L, Machineni S, et al. (2016) A Randomized, Open-label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects. Antimicrobial Agents and Chemotherapy |
| Ayalasomayajula S, Langenickel TH, Chandra P, et al. (2016) Effect of food on the oral bioavailability of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects . International Journal of Clinical Pharmacology and Therapeutics |
| Akahori M, Ayalasomayajula S, Langenickel T, et al. (2016) Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects. European Journal of Drug Metabolism and Pharmacokinetics |